About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics , Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit www.iovance.com .
Amtagvi® and its accompanying design marks, Proleukin ® , Iovance ® , and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com .
Overview
In the U.S. Cell and Gene therapy (CGT) market, access decisions span Commercial and Government Health Plans as well as clinical, formulary, finance, and value-analysis stakeholders within Authorized Treatment Centers (ATCs), integrated delivery networks (IDNs), and other provider organizations. Iovance is seeking a Senior Manager, U.S. Market Access Marketing, to translate clinical and economic evidence into differentiated value messaging and resources for AMTAGVI and pipeline therapies.
This individual will help shape and lead tactical execution of the U.S. market access strategy across payer and provider channels, focusing on ATC financial feasibility, pre-approval information exchange (PIE), total cost of care, site of care, budget impact, and cost-effectiveness.
Essential Functions and Responsibilities
Support development and lead execution of U.S. market access strategy and annual tactical plans for AMTAGVI and pipeline therapies
Support development of differentiated payer and provider value propositions that translate clinical, economic, and humanistic (PROs/HRQoL) evidence into clear, customer-relevant value messages
Lead development and lifecycle management of payer and ATC resources, including value presentations, AMCP dossiers, P&T materials, PIE materials, FDAMA Section 114 resources, economic tools, and reimbursement education tools
Partner with HEOR/RWE, Brand Marketing, Medical Affairs, BAI and other cross-functional partners to identify evidence gaps and shape analyses addressing cost of care, site of care, budget impact, cost-effectiveness, and patient outcomes
Generate actionable payer and provider insights through market research, advisory boards, field feedback, competitive intelligence, coverage monitoring, and analytics
Train and equip field teams with approved messaging, resources, and pull-through tools and incorporate field feedback to improve execution
Manage agencies, vendors, budgets, timelines, and promotional review to ensure compliant, high-quality execution and effective investment
Translate evolving payer, provider, reimbursement, policy, and competitive dynamics into recommendations for pricing, contracting, channel, evidence, and field execution
Maintain the highest standards of compliance, professional conduct, and ethical decision-making
Travel - Travel required, including overnights and some weekends (up to 20%)
Required Education, Skills, and Knowledge
Bachelor’s degree in life sciences, pharmacy, business, health economics, public health, economics, or a related field
7+ years with a…